MaaT Pharma

MaaT Pharma to Seek EMA Re-Examination for Xervyteg After CHMP Rejection

LYON, France, June 26, 2026 MaaT Pharma announced plans to request a re-examination of the European Medicines Agency (EMA)...

By cGxPwire Editor
June 27, 2026

Bio-Pharma

MaaT Pharma Receives Negative CHMP Trend for MaaT013 in aGvHD

Lyon, France, May 20, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) of...

By cGxPwire Editor
May 22, 2026

.Clinical

MaaT Pharma CHRONOS Data Reveals Poor aGvHD Survival

LYON, France, April 1, 2026 MaaT Pharma has announced the publication of CHRONOS study data in the peer-reviewed Bone...

By cGxPwire Editor
April 1, 2026

.Clinical

MaaT Pharma Advances Phase 2 Trial in ICI-Resistant NSCLC

Lyon, France, January 20, 2026 — MaaT Pharma, a late-stage clinical biotechnology company developing microbiome-driven immunotherapies, announced that the...

By cGxPwire Editor
January 21, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

MaaT Pharma to Seek EMA Re-Examination for Xervyteg After CHMP Rejection

MaaT Pharma Receives Negative CHMP Trend for MaaT013 in aGvHD

MaaT Pharma CHRONOS Data Reveals Poor aGvHD Survival

MaaT Pharma Advances Phase 2 Trial in ICI-Resistant NSCLC